Marksans Pharma smashes records: 18% revenue surge and massive profit boost in Q1 FY25
Marksans Pharma Ltd. (NSE: MARKSANS; BSE Code: 524404) has unveiled its financial results for the quarter ending June 30, 2024, highlighting a robust start to the fiscal year. The company’s revenue surged by 18% year-on-year (YoY), accompanied by a substantial expansion in gross margins and significant increases in both EBITDA and profit after tax (PAT). […]